Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

3.9K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
3.9K
Aging01:26

Aging

879
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
879
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

253
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
253
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

289
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
289
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

741
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
741
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

242
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
242

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetoencephalography biomarkers for assessing myelin content and neuronal function in acute optic neuritis.

Brain communications·2026
Same author

Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).

Neurology·2026
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

Neurology·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: Feb 19, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K

Multiple sclerosis and aging.

Céline Louapre1, Caroline Papeix1, Catherine Lubetzki1

  • 1Département de neurologie, Hôpital Pitié Salpêtrière, APHP, Paris ; UPMC Université Paris 06, UMR S 1127, CNRS UMR 7225 et ICM, Paris, France.

Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement
|October 31, 2017
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) in older adults presents unique challenges. Late-onset MS and aging with early-onset MS require tailored care, considering distinct clinical features and comorbidities for effective treatment.

Keywords:
agingcognitioncomorbiditiesmotor functionsmultiple sclerosis

More Related Videos

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Related Experiment Videos

Last Updated: Feb 19, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Area of Science:

  • Neurology
  • Immunology
  • Geriatrics

Background:

  • Multiple sclerosis (MS) is a central nervous system inflammatory demyelinating disease typically peaking around age 30.
  • An increasing number of elderly patients with MS are being observed due to improved healthcare and increased life expectancy.
  • This review examines MS in the elderly, focusing on late-onset MS (onset >50 years) and aging individuals with early-onset MS.

Purpose of the Study:

  • To review the epidemiologic, physiopathological, clinical, and therapeutic characteristics of MS in elderly patients.
  • To differentiate between late-onset MS and aging with young adult-onset MS.
  • To highlight considerations for managing MS in older populations.

Main Methods:

  • Review of existing epidemiologic studies on MS in individuals over 50.
  • Analysis of clinical presentations, including disability progression and cognitive function.
  • Examination of therapeutic challenges and considerations for disease-modifying therapies in the elderly.

Main Results:

  • Late-onset MS accounts for approximately 5% of all MS cases.
  • Compared to young-onset MS, late-onset MS typically shows a progressive course, delayed diagnosis, and higher rates of motor disability.
  • Cognitive impairment frequency and affected domains are similar between late-onset and young-onset MS in the elderly population.

Conclusions:

  • MS in the elderly, whether late-onset or aging with early-onset, necessitates specialized care.
  • Healthcare providers must address higher comorbidity prevalence and unique pharmacological considerations in older MS patients.
  • Optimizing treatment requires adapting risk/benefit assessments for disease-modifying therapies in this demographic.